The present disclosure relates generally to the field of implantable devices, and in particular, to a power adapter configured to be used with an implant.
Some known implantable devices receive power and/or energy by transcutaneously applying low frequency electrical current, similar to the transcutaneous energy transfer and application used in some known devices for delivering transcutaneous electrical stimulation. Using low frequencies, however, can cause pain, muscle contraction, discomfort, and other undesirable sensations to a subject when applied to a body of the subject. Sensitivity (e.g., of a body) to a transcutaneous electrical stimulus decreases as the frequency at which the stimulus is applied increases. Thus, a need exists for a power adapter that adapts implantable devices to receive transcutaneous energy at higher frequencies to avoid causing pain, muscle contractions, discomfort, and other undesirable sensations to a body of a subject.
In some embodiments, an apparatus includes a housing and a circuit at least partially disposed in the housing. The housing can be configured to be coupled to an implantable electrical conductor for disposition in a body. The circuit can be configured to be electrically connected to a pick-up electrode of the implantable electrical conductor when the housing is coupled to the implantable electrical conductor. When the housing is coupled to the implantable electrical conductor and implanted in a body, the circuit is configured to (1) receive, transcutaneously from a power supply, a first energy, (2) convert the first energy to a second energy, and (3) transmit, to the pick-up electrode, the second energy such that the implantable electrical conductor can apply, via a stimulating electrode, the second energy at the second frequency to a region in the body.
The drawings are not necessarily to scale. The drawings are merely schematic representations, not intended to portray specific parameters of the invention. The drawings are intended to depict only typical embodiments of disclosed systems, apparatus, and methods. In the drawings, like reference characters refer to like elements (e.g., functionally similar and/or structurally similar elements).
In some embodiments, an apparatus includes a housing and a circuit at least partially disposed in the housing (e.g., as part of a power adapter). The housing can be configured to be coupled to an implantable electrical conductor for disposition in a body. The circuit can be configured to be electrically connected to a pick-up electrode of the implantable electrical conductor when the housing is coupled to the implantable electrical conductor. When the housing is coupled to the implantable electrical conductor and implanted in a body, the circuit is configured to (1) receive, transcutaneously from a power supply, a first energy, (2) convert the first energy to a second energy, and (3) transmit, to the pick-up electrode, the second energy such that the implantable electrical conductor can apply, via a stimulating electrode, the second energy at the second frequency to a region in the body.
In some embodiments, an apparatus includes a power adapter having a housing and a circuit at least partially disposed in the housing. The housing can be configured to be coupled to an implantable device for disposition in a body. The circuit can be configured to be electrically connected to the implantable device when the housing is coupled to the implantable electrical conductor. When the housing is coupled to the implantable electrical conductor and implanted in a body, the circuit can be configured to (1) receive, transcutaneously from a power supply, a first energy having a first set of characteristics, (2) convert the first energy to a second energy having a second set of characteristics different from the first set of characteristics, and (3) transfer, to the implantable device, the second energy such that the second energy powers the implantable device.
In some embodiments, a method includes receiving, transcutaneously and from an electrical pulse generator, first energy having a first set of characteristics. The first energy is converted, via a rectification circuit, to a second energy having a second set of characteristics different from the first set of characteristics. The second energy is transferred from the rectification circuit to a stimulating electrode of an implantable electrical conductor such that the implantable electrical conductor applies, via the stimulating electrode, the second energy to a target nerve internal to a body.
For example, the power adapter 100 can be configured to receive, from the transmitter 102 and via the electrode 123, energy E1 (referred to herein as “first energy”) such as a first form or quantity of energy, power, or signals (collectively, “energy”) having a first characteristic or set of characteristics (e.g., a first frequency, a first waveform, a first burst pattern, and/or the like). The first energy E1, due to the first characteristic(s), may be unsuitable for use in powering and/or to be otherwise provided to or used by the implant 104. Accordingly, to provide energy suitable for use by the implant 104 such that the implant 104 is enabled to perform the medical procedure in the body, the power adapter 100 can be configured to transform, rectify, derive, adapt, and/or otherwise convert the first energy E1 to a second energy E2, including a second form or quantity of energy, power, or signals (“collectively, energy”) having a second characteristic or set of characteristics (e.g., a second frequency, a second waveform, a second burst pattern, and/or the like). As shown in
The housing 110 can be configured to be coupled to the implant 104 for disposition in a body therewith. The electrode 123 of the power adapter 100 can be configured to receive, transcutaneously with respect to the body, the first energy E1 (e.g., high frequency electrical bursts, low frequency pulses, etc.) for conversion and transfer to implant 104 for application (e.g., in the form of bursts or pulses, to be used by the implant 104, etc.), as described herein. Skin/partition S can include, for example, a barrier, partition, skin, and the like, such as of the body of a subject, including, for example, a person, patient, and the like. The body of the subject can include an (e.g., internal) environment, such as environment 101.
The transmitter 102 can be or include, for example, an external pulse transmitter (EPT), a power source or supply, an energy source or supply, a voltage source or supply, a (wireless) energy transfer device, a signal transmitter, and/or the like. The transmitter 102 can be configured to transmit energy (e.g., the first energy E1) into a body of a subject, which can be received, for example, by the power adapter 100 and used in and/or by implant 104 (e.g., when power adapter 100 is coupled to implant 104). For example, the transmitter 102 can be configured to transmit the energy into the body for receipt, or pick-up (e.g., of some portion of the energy), by the power adapter 100. Subsequently, the energy, after being received by the power adapter 100, can be transferred from the power adapter 100 to the implant 104 (e.g., the second energy E2, shown in
The transmitter 102 can be configured to transmit the energy into a body of a subject transcutaneously, at various levels of current, or electrical charge, and at current and/or frequency levels, to avoid causing adverse sensory or motor activation or stimulation (e.g., an undesirable local response) in and by the body. In some instances, the transmitter 102 can deliver energy transcutaneously via hydrogel, wetted cloth, and/or other electrodes attached to the skin. In some instances, the transmitter 102 can be configured to transmit the energy via output of a time-varying voltage (or electrical potential), current (or electrical charge), or electromagnetic field—at a predetermined frequency or range of frequencies, and with a predetermined waveform. In some implementations, the output from the transmitter 102 can include, for example, a time-varying flow of electrical charge. The time-varying flow of electrical charge can include, for example, electrical bursts, electrical pulses, and/or the like (“electrical burst(s)” or “burst(s)”), such as in the form of a train or series of high frequency bursts, including, for example, electrical, electromagnetic, and/or magnetic bursts. In some implementations, the output of the transmitter 102 can include a train or series of low frequency bursts, where each burst includes a single low frequency pulse. In some implementations, the output of the transmitter 102 can include a train or series of bursts including any suitable combination of one or more low frequency energy bursts and one or more high frequency energy bursts. In some instances, the one or more low frequency energy bursts can have one or more characteristics configured to result in a desirable local response in and by the body such as, for example, increased blood flow within a region of the body adjacent to or relatively near the transmitter 102, while the one or more high frequency energy bursts can be received by, for example, the power adapter 100.
In some implementations, the predetermined frequency or range of frequencies can include, for example, a frequency or range of frequencies in the range of approximately 10 kilohertz (kHz) to 60 kHz. The predetermined frequency or range of frequencies can otherwise include a frequency or range of frequencies at which the energy output from the transmitter 102 can be applied, such as to a body of a subject, without causing an undesirable response, or stimulation (“response”), such as an undesirable local motor response, in and by the body, such as shown in
In some implementations, the predetermined waveform can include, for example, a sinusoidal waveform, a rectangular waveform, a triangular waveform, or any other suitable waveform, such as shown and described with reference to
The transmitter 102 can be configured to transmit the energy by application of the output to a body of a subject at or with respect to a position, region, or location surrounding, encompassing, or adjacent to a position or location at which the power adapter 100 or the implant 104 are disposed (e.g., implanted) in the body, such as shown in
The implant 104 represents an implant such as an implantable device, including, for example, an implantable electrical conductor, and/or the like (“implant” or “implantable device” or “implantable electrical conductor”). The implant 104 can be configured to be powered by and/or otherwise use energy received from an external device such as an external transmitter or power supply (e.g., transmitter 102), via a power adapter (e.g., power adapter 100), to perform a medical procedure in a body (e.g., in environment 101) of a subject, as described herein. In some implementations, the implant 104 can include an onboard energy source, energy storage device, and/or the like, such as a battery. Such a battery can, for example, store and/or be recharged by the energy received transcutaneously.
For example, in some instances, the implant 104 can be or include an implantable electrical conductor, such as of an implantable stimulation device, or stimulator, configured to operate in the body, and to be powered, via the power adapter 100, by an external device such as the transmitter 102. In these instances, the implantable stimulation device, or stimulator, can be or include, for example, a nerve stimulator, an artificial pacemaker, and/or the like. In other instances, the implant 104 can be or include an implantable electrical conductor, such as of a fluid conveyance device, or fluid conveyor, such as a pump or compressor (e.g., insulin pump), or a vacuum, suction, or depressurizing device. In other instances, the implant 104 can be or include an implantable electrical conductor, such as a sensor, transducer, monitor, and/or recorder, including, for example, an electrocardiography (ECG) sensor, a heart rate monitor, a Holter monitor, and/or the like. The implant can otherwise be or include any suitable type and number of implantable electrical conductors.
As shown in
In some implementations, the implant 104 can be configured to receive energy from the transmitter 102 via the power adapter 100. For example, in some instances, such as when the power adapter 100 is connected to the implant 104, as shown in
The electrodes 19a and 19b can each include one or more electrodes, electrical contacts, electrical terminals, and the like. The electrode 19a can include an input electrode and the electrode 19b can include an output electrode. For example, the electrode 19a can include an input electrode such as a receiving electrode, a pick-up electrode, and/or the like (referred to herein as “pick-up electrode”). In some implementations, such as those in which the implant 104 is a stimulation device, the electrode 19b can include an output electrode such as a stimulating or stimulation electrode, a stimulation lead, and/or the like (referred to herein as “stimulating electrode” or “stimulation electrode”). In some implementations, the electrode 19a can include or be formed of a material such as a material composed of titanium (Ti), titanium-nitride (TiN), platinum-iridium (Pt—Ir) compound, and/or the like. In some implementations, the electrode 19b can include or be formed of a material such as a material composed of platinum (Pt), iridium (Ir), a platinum-iridium (Pt—Ir) compound, or alloy, and/or the like. The conductor 18 can include any suitable electrical conductor, electrical lead, and/or conductive material over which the electrodes 19a and 19b can be interconnected. For example, the conductor 18 can include a path such as a conductive path or an electrical path configured to interconnect the electrodes 19a and 19b over the implant 104. The conductor 18 can include or be formed of a material such as an inert or non-reactive material, or any other material suitable for use in a body of a subject, in accordance with embodiments described herein.
The housing 110 can be or can include any suitable type of housing or casing. For example, the housing 110 can include a housing such as an hermetically sealed casing, or can, configured to house or otherwise contain one or more circuits (e.g., circuit 120), and, having a feedthrough, inner contact (e.g., electric conductor), one or more mating features (e.g., grip mechanism assembly) configured to electrically and mechanically couple to and make contact with a pick-up electrode (e.g., electrode 19a of implant 104), and a sleeve (e.g., for mechanical and/or electrical protection). The housing 110 can be configured to at least partially house one or more circuits, including, for example, the circuit 120. The housing 110 can be configured to be coupled to an implant such as implant 104 for disposition, with implant 104 (and the circuit 120), in a body of a subject. The housing 110 can be configured to mechanically insulate the circuit 120 from the body, including, for example, from an environment in the body such as environment 101. For example, the housing 110 can be configured to insulate the circuit 120 from, for example, an environment such as environment 101 in the body of the subject, such as when the housing 110 is coupled to implant 104 and disposed in environment 101, such as by implantation with implant 104 in the body. The housing 110 can include any suitable housing capable of attaching, coupling, connecting, interconnecting, or otherwise being added, mechanically, electrically, and otherwise, to an implant such as implant 104, as described herein. The housing 110 can include any suitable type and number of components, such as including resistors, capacitors, transistors, diodes, inductors, an energy source, energy storage device, and/or the like. In some implementations, the housing 110 does not include an energy source, energy storage device, and/or the like, which can be or include, for example, a battery or other chemical source of energy. In other implementations, the housing can include an energy storage device (e.g., battery, energy storage capacitor, etc.) that can be used to power the implant 104 and/or can be recharged by receiving the transcutaneous transfer of energy, as described herein. In some implementations, the housing 110 can be or include, for example, a hermetically sealed can configured to at least partially house the circuit 120.
The circuit 120 can be or include a circuit such as an integrated circuit (IC), and/or the like. The circuit 120 can be configured to be electrically connected to an implantable device such as the implant 104 when the housing 110 is coupled to the implant 104, such as at the electrode 19a. For example, the circuit 120 can be configured to electrically connect to the implant 104, when the housing 110 is coupled to the implant 104, such as at a pick-up electrode (e.g., electrode 19a) of the implant 104, to enable the circuit 120 to provide energy (e.g., transformed power, conditioned signals) to the implant 104. The energy can be provided, by the circuit 120 and to the implant 104, via input to the implant 104 at the pick-up electrode (e.g., via a conductor or electric interface in electric communication with the electrode 19a). The circuit 120 can be configured to receive the energy (e.g., for conversion of the energy and transfer of the converted energy to implant 104) from a transmitter such as transmitter 102, as described herein. The circuit 120 can include various components, such as described herein with reference to
As an example, in use, the power adapter 100 can be configured to be implanted, in a coupled or interconnected state with implant 104, in a body of a subject. For example, the power adapter 100 can be configured to be coupled to implant 104 by attachment of the housing 110 over a pick-up electrode (electrode 19a) of the implant 104. In some instances, the power adapter 100 can be configured to be retrofit to an existing implant in a body of a subject, such as the implant 104. For example, the power adapter 100 can be configured to be mated to the existing implant such as by crimping, or the like. Once the power adapter 100 is implanted in the body with the implant 104, operating parameters, including, for example, stimulation parameters, and the like, can be set (e.g., at transmitter 102), as described herein. Accordingly, the power adapter 100—along with the transmitter 102 and the implant 104—can be configured for use, such as by the subject of the body (in which the power adapter 100 is implanted with the implant 104).
In other implementations, the power adapter 100 can be integral to the implant 104. For example, in some implementations, the power adapter 100 can be provided as part of or embedded in the implant 104, such as in a pre-coupled or -interconnected state with the implant (e.g., via interconnection to electrode 19a). Similarly stated, in such implementations, the functions of the power adapter 100 (as described herein) can be part of and/or integrated into the implant. In such implementations, a separate power adapter 100 is not needed and/or used to receive the transcutaneous energy transfer.
In some implementations, such as those in which the implant 104 is a stimulation device and the electrode 19b includes an output electrode such as a stimulating electrode, the power adapter 100 can be configured to convert the first energy E1 (e.g., from transmitter 102) to the second energy E2, for input of the second energy E2 to the implant 104 to enable the implant 104 in performing a medical procedure. In such implementations, the medical procedure can include, for example, a medical procedure in which the implant 104 is configured to provide stimulation, activation, excitation, and the like (“stimulation”) of tissue, nerves, or muscles in a body of a subject. In such implementations, the implant 104 can be configured to perform the medical procedure in the body via output of the second energy E2 at the electrode 19b. In such implementations, the second energy E2 can include, for example, a sequence of low frequency pulses or bursts and/or a sequence of high frequency pulses or bursts. Specifically, the second energy E2 can include, for example, interlaced delivery of low and high frequency energy, stimulation, bursts, and/or pulses. The medical procedure can be performed, for example, to activate a cutaneous receptor, a muscle, and/or a nerve of the body.
The circuit 220 includes a rectification circuit 221 and an electrode 223a (e.g., pick-up electrode). The rectification circuit 221 can be or include, for example, a halfwave-rectification circuit or a fullwave-rectification circuit. For example, in some instances, the rectification circuit 221 can include a resistor 222, a diode 224, and a capacitor 226. While not shown or described with respect to
The capacitor 226 can be or include, for example, a direct current (DC) blocking capacitor. The capacitor 226 can be configured to maintain a level of charge balance of the rectification circuit 221. For example, the capacitor 226 can be configured to provide charge balancing of energy transmitted from the rectification circuit 221. In some implementations, such as those in which the implant 104 is a stimulation device, a type or characteristic of the capacitor 226 can be chosen, for example, based on a characteristic (e.g., operating condition) such as tissue-electrode capacitance, such as of a pick-up electrode (e.g., electrode 19a) and a stimulating electrode (e.g., electrode 19b) of the implant 104, with respect to tissue internal to a body of a subject (e.g., in environment 101). In such implementations, the capacitor 226 can effectively be connected in series with the pick-up electrode and the stimulating electrode. In a serial connection of capacitors, the capacitor with the least amount of capacitance (i.e., the capacitor with the smallest measure of capacitance) determines the combined capacitance of the capacitors (e.g., which is substantially equal to the capacitance of the capacitor with the least relative amount of capacitance). Accordingly, the capacitor 226 can be chosen or configured to have a particular value or measure of capacitance to not decrease the overall capacitance of the path (e.g., interconnecting the capacitor 226, the pick-up electrode, and the stimulating electrode) based on the effective capacitance of the tissue-electrode capacitance of the pick-up electrode and the stimulating electrode.
As an example, where the tissue-electrode capacitance is approximately 4 microfarad (μF), the capacitor 226 can be chosen or configured to have a value or measure of capacitance of approximately 4 μF, or greater. In this example, the value of the capacitor 226 can be chosen or configured based on the tissue-electrode capacitance of the tissue internal to the body and the pick-up electrode (e.g., electrode 19a) and the stimulating electrode (e.g., electrode 19b) of the implant 104. In some implementations, the capacitor 226 can be chosen or configured to have a value or measure of capacitance that does not decrease, but supports and/or maintains an overall capacitance of the conductive path (e.g., the path interconnecting a pick-up electrode with a stimulating electrode) of the implant 104.
The diode 224 can be or include, for example, a rectifying diode. In some implementations, the diode 224 can be or include a rectifying diode such as a Schottky diode, a silicone diode, and/or the like. In some implementations, a type or characteristic of the diode 224 can be chosen, for example, based on a characteristic such as a magnitude of a voltage drop (e.g., in a forward direction) over the diode 224. For example, the type of the diode 224 can be chosen to reduce a magnitude of the voltage drop over the diode 224. In this example, the type of the diode 224 can be chosen to be or include a Schottky diode (e.g., instead of a silicon diode) to reduce the magnitude of the voltage drop over the diode 224 (e.g., compared to that of the silicon diode), and to thereby achieve a higher pick-up ratio (e.g., compared to that of a silicone diode). In some implementations, a type of the diode 224 can be chosen based on or to facilitate any suitable characteristic, such as amount of leak current, amount of back leak current, a discharge rate (e.g., of capacitor 226) between applied electrical bursts, and/or the like. For purposes of the present disclosure “pick-up” ratio refers to the amount of energy received by the implant relative to the amount of energy sent by the external transmitter. For example, a pick-up ratio of 0.5 indicates that the amount of energy received is approximately half the amount of energy sent.
The resistor 222 provides a discharge path (from rectification circuit 221) for the capacitor 226. In some implementations, a type or characteristic of the resistor 222 can be chosen, for example, based on a characteristic of the rectification circuit 221 including, for example, a discharge path characteristic of the rectification circuit 221. For example, the resistor 222 can be chosen to have a measure or value of resistance greater than an effective resistance of the diode 224, to prevent bypass (e.g., by electrical current) of the diode 224 in use (e.g., of the power adapter 200 with an implant such as implant 104). In some implementations, a type or characteristic of the resistor 222 can be chosen, for example, based on an applied frequency or frequency range of the energy (e.g., electrical signals, electrical bursts) from transmitter 102, a burst repetition frequency of the applied frequency or frequency range of the energy, a burst duration of the applied frequency or frequency range of the energy, and/or the like.
The transmitter 302 can be configured to send or otherwise provide energy to power adapter 300 (for powering and/or supplying energy to implant 304) via path 303. In some implementations, the electrical pulse generator (e.g., transmitter 102, transmitter 302) can include, for example, a power supply. The path 303, along which the energy is received, transferred, and applied, can include, for example, a portion of the body of the subject between the transmitter 302 (e.g., at a gel and/or cloth electrode of the transmitter (not shown)) and the power adapter 300 (when disposed with implant 104 in the body).
For example, the power adapter 300, the housing 310, and the circuit can be structurally and/or functionally similar to the power adapter 100, the housing 110, and the circuit 120, respectively, as described herein. The power adapter 300 can be configured to be coupled, via the housing 310, to an implant such as implant 304 for disposition in a body with implant 304, such as beneath skin and in environment 301 of the body. The power adapter 300 can be configured to be attached or coupled to implant 304 such that the pick-up electrode of implant 304 is electrically insulated from the environment 301 (e.g., when implant 304 and power adapter 300 are implanted in a body). The power adapter 300 can be configured to receive energy from the transmitter 302 for conversion and transfer to implant 304, and application, via a stimulating electrode of implant 304, to a target site or object in the body.
The transmitter 302 can be structurally and/or functionally similar to the transmitter 102, as described herein. For example, the transmitter 302 can include an external transmitter (labeled “transmitter”) and a patch (not shown) including one or more gel electrodes (labeled “gel electrode”). In some implementations, the external transmitter can include, for example, a high frequency transmitter. While shown in
Implant 304 can be structurally and/or functionally similar to implant 104, as described herein. For example, implant 304 can include an electrical conductor or lead (labeled “lead”), a stimulating electrode (labeled “stimulating electrode”), and a pick-up electrode (not shown), over which the power adapter 300 can be attached or coupled, such as described herein with reference to
In use, the power adapter 300 can be configured to receive, transcutaneously from the transmitter 302, transdermal high frequency bursts of energy (e.g., electrical energy). The energy can be received at, or can otherwise include, for example, a first frequency of between about 30 kHz and 100 kHz, or greater. In other instances, the first frequency can be between 100 kHz and 3 megahertz (MHz). In yet other instances, the first frequency can be 10 MHz or less and/or any other suitable frequency. The received energy can be converted, by the power adapter 300, to a form suitable for use in providing stimulation, activation, or excitation (e.g., of tissue, nerve, muscle) in a body of a subject. For example, the received energy can be converted, by the power adapter 300, to a second energy (e.g., stimulation current) having a second frequency less than the first frequency, such as, for example about 1 kHz. In other implementations, the second frequency can be between 1 kHz and 10 kHz. In yet other implementations, the second frequency can be between 500 Hz and 30 kHz. The energy conversion can include, for example, rectification and charge balancing via the power adapter 300. The converted energy can be transferred, from the power adapter 300 to a stimulating electrode of the implant 304, for application to a target in the body (e.g., nerve) at the stimulating electrode.
As an example, the implant 304 can be or include a lead such as a flexible electrical conductor having a length of approximately 15 cm and a diameter of approximately 1.2 mm. The stimulating electrode of the implant 304 can be positioned at or near a target object in the body, such as a nerve, or the like. The pick-up electrode of the implant 304 can be covered by attachment of the power adapter 300 to the end of the implant 304 at which the pick-up electrode is disposed. The target object can include any suitable point, region, or part of interest, such as a nerve (e.g., peroneal nerve, peripheral nerve, etc.). In some implementations, the implant 304 can include, for example, one or more stimulating electrodes having dimensions in the range of approximately 1 mm in length. In some implementations, where the implant 304 includes three or more stimulating electrodes, the stimulating electrodes can be spaced along the lead of the implant 304 at a spacing of approximately 1 mm apart. In some implementations, one or more of the stimulating electrodes of the implant 304 can be manufactured or assembled by coiling of an electrical conductor (e.g., the lead of the implant 304) on the outside of the silicone tubing (e.g., silicone sheath) and at the end of the lead, such as shown in
In some implementations, the transmitter 302 can optionally be configured to be used or programmed for use via software (e.g., residing on a device external to the transmitter). For example, the software can reside or otherwise be hosted on any suitable type of compute device (e.g., mobile device, tablet computer, server). For example, the software can be executed at a compute device to generate and send signals (e.g., including commands) to the transmitter 302 for execution (e.g., at the transmitter 302), and the transmitter 302 can be configured to receive, from the compute device, one or more of the signals, including, for example, a signal corresponding to a command configured to be executed at the transmitter 302. The signals can include, for example, machine- or processor-readable code and/or instructions configured to be stored on and/or executed at the transmitter 302. In some implementations, the code can include instructions configured to be executed at the transmitter 302, such as to set or specify one or more operating parameters, stimulation parameters, and/or the like, of and/or at the transmitter 302. For example, one or more of the operating parameters of the transmitter 302 can include a particular stimulation routine to be applied (e.g., via the implant 104), a particular stimulation intensity to be applied (e.g., transcutaneously to the body), an applied frequency or frequency range of the energy to be applied, and so on. The software can be configured for use, for example, by a user or operator such as a clinician, a patient, and/or the like.
In some implementations, the software by which the transmitter 302 can optionally be configured to be used or programmed for use can be stored, for example, at a compute device such as a tablet compute device. In some instances, the compute device can be configured to communicate with the transmitter 302 via a communications link such as a Bluetooth Low Energy (BLE) communications link, or the like. In some instances, the software can be configured to enable access to data including, for example, patient demographic information, session data, patient stimulation profiles, and the like. In some instances, the software can reside or otherwise be hosted for use via a smartphone platform (e.g., iOS, Android). In some instances, the software can include, for example, a mobile app. In some implementations, the software can be configured to enable, for example, use tracking, system error or fault notification, and/or the like. In some implementations, the software can be configured to control various functions of the transmitter 302, including, for example, selection of a stimulation program or routine (e.g., as pre-defined by a user such as a clinician), stimulation activation and deactivation (e.g., turning the transmitter 302 on and off), increase or decrease (applied) stimulation intensity, and so on. In some implementations, the software can be configured to provide (e.g., via a display, transducer such as a speaker) an indication (e.g., visual, auditory) as to operating status, such as with respect to selected stimulation program, selected stimulation intensity level, good or bad electrode connection, among other types of indications of errors or operating status.
At 42, the method 401 includes receiving (e.g., via the power adapter 100, 200, and/or 300), transcutaneously and from an electrical pulse generator (e.g., the transmitter 102 and/or 302), first energy at a first frequency and/or first waveform. At 44, the method 401 includes converting, via a rectification circuit (e.g., the rectification circuit 221), the first energy to a second energy. In some implementations, the second energy can have a second frequency different from the first frequency and/or a second waveform different from the first waveform. At 46, the method 401 includes transferring, from the rectification circuit, the second energy to a stimulating electrode (e.g., the electrode 19b shown in
In some implementations, the second energy can be transferred from the rectification circuit (e.g., the rectification circuit 221) to a pick-up electrode (e.g., the electrode 19a) of the implantable electrical conductor (e.g., the implant 104), for subsequent transfer and routing via the implantable electrical conductor (e.g., the conductor 18 of the implant 104) to the stimulating electrode (e.g., the electrode 19b), and application, at the stimulating electrode, to a target nerve internal to the body. In some implementations, the second energy can be transferred from the rectification circuit to the implantable electrical conductor, and in particular, the stimulating electrode, to enable application of the second energy to the target internal to the body. In some implementations, the first energy can include, for example, alternating current. In some implementations, the second energy can include, for example, pulsating direct current. In some implementations, the first frequency can include, for example, a frequency in the range of about 30 kHz and 100 kHz. When the apparatus is not coupled to the implantable electrical conductor (e.g., via the housing 110, 210, and/or 310), the pick-up electrode of the implantable electrical conductor can be configured to receive, transcutaneously (e.g., from the electrical pulse generator), third energy at substantially the second frequency and/or second waveform.
With reference to
The transmitter 502a can be configured to transmit the energy by application (e.g., via the electrode patch 57a) of the output to the body (e.g., at a skin surface of the body), transcutaneously, such as along or with respect to a path (e.g., electrical path, conductive path) at least partially disposed internal to the body, and interconnecting the transmitter 502a and the implant 504. The path can include, for example, the electrode patch 57a, a first portion of the body 50a, the implant 504 (e.g., via the electrodes 59a and 59b), a second portion of the body 50b, an electrode patch 57b, and the transmitter 502a. A portion of the applied transcutaneous stimulation (e.g., 10%-20%) can be picked up or received by the implant 504, at electrode 59a, and can be transferred and/or routed, to electrode 59b and along the implant 104 (e.g., via the conductor 18). The electrode 59a can include, for example, a pick-up electrode. The electrode 59b can include, for example, a stimulating electrode.
In some implementations, the implant 504 can include insulation such as a silicone backfill and tubing, disposed about a lead body (e.g., the conductor 18 shown in
In some implementations, the energy frequency 51a at the pick-up electrode and the energy frequency 51b at the stimulating electrode can be similar, or substantially equal or identical. In some implementations, the waveform can also be similar, or substantially equal or identical, with the exception of the signal amplitude. The transmitter 502a can be configured to apply and deliver energy transcutaneously at a low applied frequency or frequency range (e.g., below 10 kHz) for stimulation at the low applied frequency at and by the electrode 59b.
With reference to
The transmitter 502b can be configured to send the first energy at a frequency of approximately 35 kHz-50 kHz, to avoid causing sensation in the body of the subject. The transmitter 502b can be configured to send the first energy at a frequency to avoid causing direct activation of the nerves about the location of application of the transcutaneous stimulation to the body. The transmitter 502b can be configured to transmit the energy by application (e.g., via the electrode patch 57a) to the body (e.g., at a skin surface of the body), transcutaneously, such as along or with respect to a path (e.g., electrical path, conductive path) at least partially disposed internal to the body, and interconnecting the transmitter 502b, the power adapter 500, and the implant 504. The path can include, for example, the electrode patch 57a, a first portion of the body 50a, the power adapter 500 (e.g., via the electrode 123 and/or 223a in
A portion of the applied transcutaneous stimulation such as between approximately 10%-20% (e.g., from the transmitter 502b) can be picked up by the pick-up electrode of the power adapter 500, in the form of the first energy 52a (e.g., having a first frequency and/or having a first waveform) and converted, by a rectification circuit (e.g., the rectification circuit 221) of a circuit (e.g., the circuit 120 and/or 220) of the power adapter 500 (e.g., at least partially disposed in the housing 510 of the power adapter 500), to second energy 52b (e.g., having a second frequency and/or having a second waveform). The second energy 52b can include, for example, low frequency bursts, high frequency bursts, and/or the like. The second energy 52b can be routed to the electrode 59b for application, via one or more electrodes at or of the electrode 59b, to a target such as a target peripheral nerve, or any other suitable site in the body, such as to treat pain. In some implementations, the second energy 52b can include, for example, a sinusoidal waveform, a rectangular waveform, a triangular waveform, or the like. For example, the power adapter 500 (via the circuit disposed in the housing 510) can be configured to operate in a manner similar to that of an AM radio receiver, by demodulating energy including signals such as high frequency bursts (e.g., carrier wave) and detecting the low frequency (e.g., modulated) signal. As such, the power adapter 500 can be configured to be retrofit and/or adapted for use in or with an implant (e.g., the implant 504) normally configured to receive energy at a first frequency (e.g., a low frequency) and/or having a first waveform, such that the implant can receive energy at a second frequency (e.g., low frequency pulses, high frequency bursts) and/or having a second waveform.
In some implementations, the rectification circuit of the circuit at least partially disposed in housing 510 of the power adapter 500 can include a rectifying diode (e.g., the diode 224) oriented in a cathodic orientation, such as shown in
While the transmitters 502a is described above as transmitting the first energy 51a having a relatively low frequency and the transmitter 502b is described above as transmitting the first energy 52a having a relatively high frequency, in some embodiments, a transmitter can be configured to transmit energy that includes any suitable combination of the energy 51a (e.g., the relatively low frequency) and the energy 52a (e.g., the relatively high frequency). In such implementations, the transmitter can transmit the energy in any suitable pattern, combination, sequence, interlaced or non-interlaced series, time-dependent bursts or pulses, random bursts or pulses, and/or the like. In some instances, the relatively low frequency energy can be configured to result in and/or otherwise cause a desirable local response such as, for example, increased blood flow or other desirable response within a region of the body adjacent and/or near the transmitter, while the relatively high frequency energy can be received by the power adapter and transmitted to the implant, as described above.
In some implementations, the housing 610 can be configured to be coupled, for example, to, on, and/or over implant 604, such that the housing 610 at least partially covers an end of implant 604, such as shown in
The pick-up electrode 69a of the implant 604 is shown in
In some implementations, a housing 710 of the power adapter 700 can be configured to be coupled, for example, to, on, and/or over implant 704, such that the housing 710 at least partially covers an end of implant 704, such as shown in
As shown in
As shown in
As shown, the circuit 821A includes a capacitor C (e.g., the capacitor 226) in series with a resistor R (e.g., the resistor 222), which is in parallel with a diode D (e.g., the diode 224). The diode D can include a rectifying diode. The capacitor C can include a DC blocking capacitor, as described above with respect to capacitor 226 in
As shown, the circuits 821B and 821C can include a capacitor C (e.g., the capacitor 226) in series with a resistor R (e.g., the resistor 222) and a diode D (e.g., the diode 224)—the resistor R is in parallel with the diode D. Moreover, each circuit 821B and 821C can include an electrostatic discharge (ESD) protection circuit, such as shown in
As shown, each circuit 921A and 921B includes a capacitor C (e.g., the capacitor 226) in series with a resistor R (e.g., the resistor 222) and a diode D (e.g., the diode 224)—the resistor R is in parallel with the diode D. Moreover, each circuit 921 can include a capacitor Cmri configured to provide magnetic resonance imaging (MRI) protection. For example, as shown in
As shown, each circuit 1021A and 1021B includes a capacitor C (e.g., the capacitor 226) in series with a resistor R (e.g., the resistor 222) and a diode D (e.g., diode 224)—the resistor R is in parallel with the diode D. As shown in
While the circuit 1021A is shown in
The power adapters described in detail herein can be configured to receive a first energy and to convert and output a second energy. For example, the power adapters can include one or more circuits having any suitable components, as described in detail above with reference to specific embodiments. In some implementations, a power adapter can be configured to convert energy received from the transmitter (e.g., the first energy) to an energy (e.g., a second energy) having one or more different characteristics. For example, in some embodiments, the power adapter and/or at least a portion thereof can be configured to rectify the first energy received from the transmitter such that a second energy having a rectified waveform (e.g., a halfwave rectified) waveform or a fullwave rectified waveform) is transferred to, for example, a pick-up electrode of an implant. In some instances, the rectification can be, for example, a one-way rectification (also referred to as halfwave-rectification). For example,
While the power adapter 1200b is shown and described as including the circuit 1220b at or near the proximal end and the distal electrode 1228b at or near the distal end, in other embodiments, a power adapter configured to perform two-way of fullwave rectification on energy received from a transmitter can have any suitable arrangement. For example,
In some embodiments, the lead can have a length of about 7.0 centimeters (cm). In other embodiments, the lead can be longer than 7.0 cm or can be shorter than 7.0 cm. In some embodiments, the length of the lead and/or power adapter 1300 can be at least partially based on a size and/or shape of the transmitter 1302 used therewith. For example, as shown in
The kit 1405 represents a tool set including various implements and tools by which to facilitate disposition of the implant in a body of a subject.
The lead adapter can include a lead adapter configured to couple the implant (e.g., 104, 304, 504, and/or 604) to a transmitter (e.g., transmitter 102) such as during an intraoperative implantation procedure. When provided as part of the kit 1405, the implant can include electrodes or probes, and be provided with an energy (e.g., signal, power) input end (e.g., at pick-up electrode) and an energy (e.g., signal, power) output end (e.g., at stimulating electrode, transducing end, sensing end), such as described herein. The implant can be provided in a loading or deployment device, or loader, configured to facilitate implantation of the implant in a body.
The loading or deployment device can be configured to maintain the implant in a sterile condition before and during end-use, and to reduce a risk of contamination during implantation of the implant (with the power adapter) in a body. The loading or deployment device can be configured to facilitate implantation of the implant (e.g., with the stimulating electrode end being the leading end).
The introducer set can include, for example, an incision-forming tool, a hollow tube (e.g., through which to dispose the power adapter and the implant in a body of a subject), and a seal. For example, the introducer set can include a trocar including an obturator, a tube such as a cannula, and a medical seal. The tunneling needle and the tunneling needle stylet can include a tunneling needle configured to facilitate access to a body, such for subsequent implantation of the implant (e.g., and the power adapter) in the body.
The anchor can include, for example, a silicon anchor. The anchor can otherwise include an anchor formed of any suitable material, such as a non-reactive or inert material, and the like. The anchor can be configured to fix the implant (e.g., along with the power adapter) in position in a body when disposed in the body. For example, the anchor can include a 4-pronged anchor configured to prevent or reduce lead migration after implantation. The kit 1405 can otherwise include any other suitable tool or implement for facilitating access to a body of a subject, and disposition (e.g., via implantation) of the power adapter and the implant in the body, in accordance with embodiments disclosed herein. For example, the kit 1405 can include tools and implements (provided and supplied in various conditions) such as listed in Table 1, below.
Detailed embodiments of the present disclosure have been disclosed herein or purposes of describing and illustrating claimed structures and methods that can be embodied in various forms, and are not intended to be exhaustive in any way, or limited to the disclosed embodiments. Many modifications and variations will be apparent without departing from the scope of the disclosed embodiments. The terminology used herein was chosen to best explain the principles of the one or more embodiments, practical applications, or technical improvements over current technologies, or to enable understanding of the embodiments disclosed herein. As described, details of well-known features and techniques can be omitted to avoid unnecessarily obscuring the embodiments of the present disclosure.
References in the specification to “one embodiment,” “an embodiment,” “an example embodiment,” or the like, indicate that the embodiment described can include one or more particular features, structures, or characteristics, but it shall be understood that such particular features, structures, or characteristics may or may not be common to each and every disclosed embodiment disclosed herein. Moreover, such phrases do not necessarily refer to any one particular embodiment per se. As such, when one or more particular features, structures, or characteristics is described in connection with an embodiment, it is submitted that it is within the knowledge of those skilled in the art to affect such one or more features, structures, or characteristics in connection with other embodiments, where applicable, whether or not explicitly described.
Parameters, dimensions, materials, and configurations described herein are meant to be examples and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto; and that embodiments can be practiced otherwise than as specifically described and claimed. Embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the scope of the present disclosure.
As used herein, the terms “about” and/or “approximately” when used in conjunction with values and/or ranges generally refer to those values and/or ranges near to a recited value and/or range. In some instances, the terms “about” and “approximately” may mean within ±10% of the recited value. For example, in some instances, “approximately a diameter of an instrument” may mean within ±10% of the length of the instrument. The terms “about” and “approximately” may be used interchangeably. Similarly, the term “substantially” when used in conjunction with physical and/or geometric feature(s), structure(s), characteristic(s), relationship(s), etc. is intended to convey that the feature(s), structure(s), characteristic(s), relationship(s), etc. so defined is/are nominally the feature(s), structure(s), characteristic(s), relationship(s), etc. As one example, a first quantity that is described as being “substantially equal” to a second quantity is intended to convey that, although equality may be desirable, some variance can occur. Such variance can result from manufacturing tolerances, limitations, approximations, and/or other practical considerations. Thus, the term “substantially”.
While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. Where schematics and/or embodiments described above indicate certain components arranged in certain orientations or positions, the arrangement of components may be modified. While the embodiments have been particularly shown and described, it will be understood that various changes in form and details may be made. Although various embodiments have been described as having particular features and/or combinations of components, other embodiments are possible having a combination of any features and/or components from any of embodiments described herein.
The specific configurations of the various components can also be varied. For example, the size and specific shape of the various components can be different from the embodiments shown, while still providing the functions as described herein. More specifically, the size and shape of the various components can be specifically selected for a desired or intended usage. Thus, it should be understood that the size, shape, and/or arrangement of the embodiments and/or components thereof can be adapted for a given use unless the context explicitly states otherwise.
Where methods and/or events described above indicate certain events and/or procedures occurring in certain order, the ordering of certain events and/or procedures may be modified. Additionally, certain events and/or procedures may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above.
This application is a division of U.S. patent application Ser. No. 16/504,623, filed on Jul. 8, 2019, entitled “Implantable Power Adapter,” the disclosure of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3204637 | Frank et al. | Sep 1965 | A |
3426748 | Bowers et al. | Feb 1969 | A |
3494907 | Merijan et al. | Feb 1970 | A |
3563968 | Merijan et al. | Feb 1971 | A |
3796221 | Hagfors | Mar 1974 | A |
4269198 | Stokes | May 1981 | A |
4271847 | Stokes | Jun 1981 | A |
4479500 | Smits | Oct 1984 | A |
4506673 | Bonnell | Mar 1985 | A |
4515167 | Hochman | May 1985 | A |
4559951 | Dahl et al. | Dec 1985 | A |
4574814 | Buffet | Mar 1986 | A |
4658835 | Pohndorf | Apr 1987 | A |
4664120 | Hess | May 1987 | A |
4702732 | Powers et al. | Oct 1987 | A |
4917104 | Rebell | Apr 1990 | A |
4989617 | Memberg et al. | Feb 1991 | A |
5012806 | De Bellis | May 1991 | A |
5016646 | Gotthardt et al. | May 1991 | A |
5030457 | Ng et al. | Jul 1991 | A |
5217028 | Dutcher et al. | Jun 1993 | A |
5231996 | Bardy et al. | Aug 1993 | A |
5300107 | Stokes et al. | Apr 1994 | A |
5324316 | Schulman et al. | Jun 1994 | A |
5330489 | Green et al. | Jul 1994 | A |
5405367 | Schulman et al. | Apr 1995 | A |
5441527 | Erickson et al. | Aug 1995 | A |
5545206 | Carson | Aug 1996 | A |
5653742 | Parker et al. | Aug 1997 | A |
5769858 | Pearson et al. | Jun 1998 | A |
5814090 | Latterell et al. | Sep 1998 | A |
5849033 | Mehmanesh et al. | Dec 1998 | A |
5861019 | Sun et al. | Jan 1999 | A |
5871531 | Struble | Feb 1999 | A |
5897585 | Williams | Apr 1999 | A |
5919222 | Hjelle et al. | Jul 1999 | A |
5931864 | Chastain et al. | Aug 1999 | A |
5939453 | Heller et al. | Aug 1999 | A |
5944729 | Blake | Aug 1999 | A |
5954759 | Swoyer et al. | Sep 1999 | A |
5968543 | Heller et al. | Oct 1999 | A |
6006122 | Smits | Dec 1999 | A |
6083216 | Fischer, Sr. | Jul 2000 | A |
6153664 | Wise et al. | Nov 2000 | A |
6178355 | Williams et al. | Jan 2001 | B1 |
6178356 | Chastain et al. | Jan 2001 | B1 |
6181973 | Ceron et al. | Jan 2001 | B1 |
6214032 | Loeb et al. | Apr 2001 | B1 |
6240322 | Peterfeso et al. | May 2001 | B1 |
6289251 | Huepenbecker et al. | Sep 2001 | B1 |
6304786 | Heil, Jr. et al. | Oct 2001 | B1 |
6330481 | Van Wijk et al. | Dec 2001 | B1 |
6438428 | Axelgaard et al. | Aug 2002 | B1 |
6505074 | Boveja et al. | Jan 2003 | B2 |
6505082 | Scheiner et al. | Jan 2003 | B1 |
6510347 | Borkan | Jan 2003 | B2 |
6517559 | O'Connell | Feb 2003 | B1 |
6580949 | Tsuboi et al. | Jun 2003 | B1 |
6650922 | Kurata et al. | Nov 2003 | B2 |
6666208 | Schumacher et al. | Dec 2003 | B1 |
6735474 | Loeb et al. | May 2004 | B1 |
6735475 | Whitehurst et al. | May 2004 | B1 |
6754472 | Williams et al. | Jun 2004 | B1 |
6788979 | Axelgaard et al. | Sep 2004 | B1 |
6829508 | Schulman et al. | Dec 2004 | B2 |
6847844 | Sun et al. | Jan 2005 | B2 |
6896675 | Leung et al. | May 2005 | B2 |
6909918 | Stypulkowski | Jun 2005 | B2 |
6913765 | Li et al. | Jul 2005 | B2 |
6925318 | Bencini | Aug 2005 | B2 |
6939569 | Green et al. | Sep 2005 | B1 |
6941171 | Mann et al. | Sep 2005 | B2 |
6961623 | Prochazka | Nov 2005 | B2 |
6997735 | Ehr et al. | Feb 2006 | B2 |
6999819 | Swoyer et al. | Feb 2006 | B2 |
7004948 | Pianca et al. | Feb 2006 | B1 |
7013179 | Carter et al. | Mar 2006 | B2 |
7043299 | Erlinger et al. | May 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7062330 | Boveja et al. | Jun 2006 | B1 |
7101394 | Hamm et al. | Sep 2006 | B2 |
7101840 | Brocchini et al. | Sep 2006 | B2 |
7146222 | Boling | Dec 2006 | B2 |
7155292 | Kawula et al. | Dec 2006 | B2 |
7162303 | Levin et al. | Jan 2007 | B2 |
7187980 | Osypka et al. | Mar 2007 | B2 |
7191018 | Gielen et al. | Mar 2007 | B2 |
7210210 | Lippitt et al. | May 2007 | B2 |
7212869 | Wahlstrom et al. | May 2007 | B2 |
7324853 | Ayal et al. | Jan 2008 | B2 |
7349742 | Heil et al. | Mar 2008 | B2 |
7389145 | Kilgore et al. | Jun 2008 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7536226 | Williams et al. | May 2009 | B2 |
8025668 | McCartney | Sep 2011 | B2 |
8027718 | Spinner et al. | Sep 2011 | B2 |
8032220 | Kuzma | Oct 2011 | B2 |
8170675 | Alataris et al. | May 2012 | B2 |
8209021 | Alataris et al. | Jun 2012 | B2 |
8255057 | Fang et al. | Aug 2012 | B2 |
8332029 | Glukhovsky et al. | Dec 2012 | B2 |
8355792 | Alataris et al. | Jan 2013 | B2 |
8359102 | Alataris et al. | Jan 2013 | B2 |
8359103 | Alataris et al. | Jan 2013 | B2 |
8361067 | Pellegrino et al. | Jan 2013 | B2 |
8396559 | Alataris et al. | Mar 2013 | B2 |
8406886 | Gaunt et al. | Mar 2013 | B2 |
8414571 | Pellegrino et al. | Apr 2013 | B2 |
8419730 | Pellegrino et al. | Apr 2013 | B2 |
8419731 | Pellegrino et al. | Apr 2013 | B2 |
8423147 | Alataris et al. | Apr 2013 | B2 |
8425507 | Pellegrino et al. | Apr 2013 | B2 |
8428728 | Sachs | Apr 2013 | B2 |
8428748 | Alataris et al. | Apr 2013 | B2 |
8509905 | Alataris et al. | Aug 2013 | B2 |
8509906 | Walker et al. | Aug 2013 | B2 |
8535309 | Pellegrino et al. | Sep 2013 | B2 |
8538517 | Glukhovsky et al. | Sep 2013 | B2 |
8554326 | Alataris et al. | Oct 2013 | B2 |
8583256 | Tracey et al. | Nov 2013 | B2 |
8588930 | Diubaldi et al. | Nov 2013 | B2 |
8613744 | Pellegrino et al. | Dec 2013 | B2 |
8623014 | Pellegrino et al. | Jan 2014 | B2 |
8628528 | Pellegrino et al. | Jan 2014 | B2 |
8649874 | Alataris et al. | Feb 2014 | B2 |
8676331 | Parker | Mar 2014 | B2 |
8694108 | Alataris et al. | Apr 2014 | B2 |
8694109 | Alataris et al. | Apr 2014 | B2 |
8706230 | Rousso et al. | Apr 2014 | B2 |
8712533 | Alataris et al. | Apr 2014 | B2 |
8718781 | Alataris et al. | May 2014 | B2 |
8718782 | Alataris et al. | May 2014 | B2 |
8751003 | Diubaldi et al. | Jun 2014 | B2 |
8768472 | Fang et al. | Jul 2014 | B2 |
8774926 | Alataris et al. | Jul 2014 | B2 |
8792988 | Alataris et al. | Jul 2014 | B2 |
8798754 | Knudson et al. | Aug 2014 | B2 |
8805519 | Parker et al. | Aug 2014 | B2 |
8808284 | Pellegrino et al. | Aug 2014 | B2 |
8838248 | Walker et al. | Sep 2014 | B2 |
8843188 | Kilgore et al. | Sep 2014 | B2 |
8849410 | Walker et al. | Sep 2014 | B2 |
8862225 | Glukhovsky et al. | Oct 2014 | B2 |
8862239 | Alataris et al. | Oct 2014 | B2 |
8868192 | Alataris et al. | Oct 2014 | B2 |
8874217 | Alataris et al. | Oct 2014 | B2 |
8874221 | Alataris et al. | Oct 2014 | B2 |
8874222 | Alataris et al. | Oct 2014 | B2 |
8880177 | Alataris et al. | Nov 2014 | B2 |
8880189 | Lipani | Nov 2014 | B2 |
8882764 | Sutton et al. | Nov 2014 | B2 |
8886326 | Alataris et al. | Nov 2014 | B2 |
8886327 | Alataris et al. | Nov 2014 | B2 |
8886328 | Alataris et al. | Nov 2014 | B2 |
8892209 | Alataris et al. | Nov 2014 | B2 |
8903494 | Goldwasser et al. | Dec 2014 | B2 |
8903502 | Perryman et al. | Dec 2014 | B2 |
8918181 | Ackermann et al. | Dec 2014 | B2 |
8958880 | DeGiorgio et al. | Feb 2015 | B2 |
8965482 | Thacker et al. | Feb 2015 | B2 |
8989865 | Alataris et al. | Mar 2015 | B2 |
8992522 | Pellegrino et al. | Mar 2015 | B2 |
8992523 | Pellegrino et al. | Mar 2015 | B2 |
8996137 | Ackermann et al. | Mar 2015 | B2 |
9002458 | Pal et al. | Apr 2015 | B2 |
9002460 | Parker | Apr 2015 | B2 |
9002467 | Smith et al. | Apr 2015 | B2 |
9014811 | Pal et al. | Apr 2015 | B2 |
9017325 | Pellegrino et al. | Apr 2015 | B2 |
9023038 | Pellegrino et al. | May 2015 | B2 |
9039701 | Pellegrino et al. | May 2015 | B2 |
9072886 | Gaunt et al. | Jul 2015 | B2 |
9095723 | Ackermann et al. | Aug 2015 | B2 |
9101769 | Edgerton et al. | Aug 2015 | B2 |
9173676 | Pellegrino et al. | Nov 2015 | B2 |
9174006 | Vosseler et al. | Nov 2015 | B2 |
9180298 | Alataris et al. | Nov 2015 | B2 |
9220897 | Perryman et al. | Dec 2015 | B2 |
9233244 | Pal et al. | Jan 2016 | B2 |
9238139 | DeGiorgio et al. | Jan 2016 | B2 |
9242113 | Smith et al. | Jan 2016 | B2 |
9248278 | Crosby et al. | Feb 2016 | B2 |
9248293 | Walker et al. | Feb 2016 | B2 |
9259241 | Pellegrino et al. | Feb 2016 | B2 |
9265522 | Pellegrino et al. | Feb 2016 | B2 |
9265956 | Ackermann et al. | Feb 2016 | B2 |
9278215 | Thacker et al. | Mar 2016 | B2 |
9283387 | Thacker et al. | Mar 2016 | B2 |
9283388 | Thacker et al. | Mar 2016 | B2 |
9295839 | Thacker et al. | Mar 2016 | B2 |
9327121 | Thacker et al. | May 2016 | B2 |
9327125 | Alataris et al. | May 2016 | B2 |
9327126 | Alataris et al. | May 2016 | B2 |
9327127 | Alataris et al. | May 2016 | B2 |
9333357 | Alataris et al. | May 2016 | B2 |
9333358 | Alataris et al. | May 2016 | B2 |
9333359 | Alataris et al. | May 2016 | B2 |
9333360 | Alataris et al. | May 2016 | B2 |
9345891 | Thacker et al. | May 2016 | B2 |
9352164 | Smith et al. | May 2016 | B2 |
9358388 | Parker et al. | Jun 2016 | B2 |
9364661 | Kilgore et al. | Jun 2016 | B2 |
9364674 | Cook et al. | Jun 2016 | B2 |
9387327 | Alataris et al. | Jul 2016 | B2 |
9393409 | Edgerton et al. | Jul 2016 | B2 |
9393430 | Demers et al. | Jul 2016 | B2 |
9399126 | Pal et al. | Jul 2016 | B2 |
9403011 | Mercanzini | Aug 2016 | B2 |
9403013 | Walker et al. | Aug 2016 | B2 |
9403020 | Wingeier | Aug 2016 | B2 |
9409011 | Tai et al. | Aug 2016 | B2 |
9409019 | Walker et al. | Aug 2016 | B2 |
9409023 | Burdick et al. | Aug 2016 | B2 |
9415218 | Edgerton et al. | Aug 2016 | B2 |
9421064 | Pellegrino et al. | Aug 2016 | B2 |
9440065 | Ackermann et al. | Sep 2016 | B2 |
9440070 | Goldwasser et al. | Sep 2016 | B2 |
9457186 | Gross | Oct 2016 | B2 |
9474891 | Demers et al. | Oct 2016 | B2 |
9480842 | Alataris et al. | Nov 2016 | B2 |
9486279 | Pellegrino et al. | Nov 2016 | B2 |
9504827 | DeGiorgio et al. | Nov 2016 | B2 |
9511223 | DeGiorgio et al. | Dec 2016 | B2 |
9511226 | Pelizzone et al. | Dec 2016 | B2 |
9517351 | Charlesworth et al. | Dec 2016 | B2 |
9526909 | Stahmann et al. | Dec 2016 | B2 |
9592388 | Parker et al. | Mar 2017 | B2 |
9592391 | Stahmann et al. | Mar 2017 | B2 |
9597521 | Plotkin et al. | Mar 2017 | B2 |
9604059 | Parker | Mar 2017 | B2 |
RE46356 | Pellegrino et al. | Apr 2017 | E |
9643022 | Mashiach et al. | May 2017 | B2 |
9669230 | Koop | Jun 2017 | B2 |
9682236 | DeGiorgio et al. | Jun 2017 | B2 |
9687652 | Franke et al. | Jun 2017 | B2 |
9694189 | Maile et al. | Jul 2017 | B2 |
9713707 | Oron et al. | Jul 2017 | B2 |
9717627 | Kuzma et al. | Aug 2017 | B2 |
9724107 | Pellegrino et al. | Aug 2017 | B2 |
9724151 | Edidin | Aug 2017 | B2 |
9737702 | Ackermann et al. | Aug 2017 | B2 |
9737712 | Franke et al. | Aug 2017 | B2 |
9757554 | Dar et al. | Sep 2017 | B2 |
9757570 | Maile et al. | Sep 2017 | B2 |
9764146 | Oron et al. | Sep 2017 | B2 |
9764150 | Loudin et al. | Sep 2017 | B2 |
9770583 | Gupta et al. | Sep 2017 | B2 |
9775627 | Patel et al. | Oct 2017 | B2 |
9789314 | Perryman et al. | Oct 2017 | B2 |
9808631 | Maile et al. | Nov 2017 | B2 |
9821159 | Ackermann et al. | Nov 2017 | B2 |
9833614 | Gliner | Dec 2017 | B1 |
9848944 | Sutton et al. | Dec 2017 | B2 |
9849289 | Mashiach et al. | Dec 2017 | B2 |
9853743 | Schmidt et al. | Dec 2017 | B2 |
9855032 | Mashiach et al. | Jan 2018 | B2 |
9861812 | Gross et al. | Jan 2018 | B2 |
9895539 | Heit et al. | Feb 2018 | B1 |
9907950 | Perryman et al. | Mar 2018 | B1 |
9907958 | Edgerton et al. | Mar 2018 | B2 |
9931508 | Burdick et al. | Apr 2018 | B2 |
9943686 | Mashiach | Apr 2018 | B2 |
9950166 | Mashiach et al. | Apr 2018 | B2 |
9956397 | Loudin et al. | May 2018 | B2 |
9956405 | Goldwasser et al. | May 2018 | B2 |
9956414 | Kane et al. | May 2018 | B2 |
9968780 | Pal et al. | May 2018 | B2 |
9968783 | Bullinga et al. | May 2018 | B2 |
9968787 | Kane et al. | May 2018 | B2 |
9993642 | Gerasimenko et al. | Jun 2018 | B2 |
9993645 | Walker et al. | Jun 2018 | B2 |
9993654 | Smith et al. | Jun 2018 | B2 |
10004896 | Oron et al. | Jun 2018 | B2 |
10016600 | Creasey et al. | Jul 2018 | B2 |
10016601 | Cook et al. | Jul 2018 | B2 |
10028753 | Pellegrino et al. | Jul 2018 | B2 |
10029107 | Webb et al. | Jul 2018 | B1 |
10039917 | Kilgore et al. | Aug 2018 | B2 |
10046167 | Schmidt et al. | Aug 2018 | B2 |
10050700 | Ludwig et al. | Aug 2018 | B2 |
10052097 | Mashiach et al. | Aug 2018 | B2 |
10058704 | Degiorgio et al. | Aug 2018 | B2 |
10065041 | Huelskamp et al. | Sep 2018 | B2 |
10071241 | Bhadra et al. | Sep 2018 | B2 |
10076665 | Parker | Sep 2018 | B2 |
10092750 | Edgerton et al. | Oct 2018 | B2 |
10092760 | Kane et al. | Oct 2018 | B2 |
10105540 | Oron et al. | Oct 2018 | B2 |
10111704 | Pellegrino et al. | Oct 2018 | B2 |
10112048 | Franke et al. | Oct 2018 | B2 |
10124166 | Edgerton et al. | Nov 2018 | B2 |
10124178 | Oron et al. | Nov 2018 | B2 |
10137299 | Lu et al. | Nov 2018 | B2 |
10137305 | Kane et al. | Nov 2018 | B2 |
10143846 | Ackermann et al. | Dec 2018 | B2 |
10149978 | Park | Dec 2018 | B1 |
10155108 | Ackermann et al. | Dec 2018 | B2 |
10159842 | Kane et al. | Dec 2018 | B2 |
10173065 | Walker et al. | Jan 2019 | B2 |
10179241 | Walker et al. | Jan 2019 | B2 |
10179244 | LeBaron et al. | Jan 2019 | B2 |
10183170 | Kane et al. | Jan 2019 | B2 |
10195433 | Alataris et al. | Feb 2019 | B2 |
10195434 | Bhadra et al. | Feb 2019 | B2 |
10195435 | Degiorgio et al. | Feb 2019 | B2 |
10207108 | Franke et al. | Feb 2019 | B2 |
10213610 | Maile et al. | Feb 2019 | B2 |
10220208 | Alataris et al. | Mar 2019 | B2 |
10220209 | Alataris et al. | Mar 2019 | B2 |
10220213 | Huelskamp et al. | Mar 2019 | B2 |
10226626 | Alataris et al. | Mar 2019 | B2 |
10226631 | Kane et al. | Mar 2019 | B2 |
10238861 | Ackermann et al. | Mar 2019 | B2 |
10238862 | Cook et al. | Mar 2019 | B2 |
10238863 | Gross et al. | Mar 2019 | B2 |
10238872 | Pivonka et al. | Mar 2019 | B2 |
10238874 | Perryman et al. | Mar 2019 | B2 |
10238882 | Koop | Mar 2019 | B2 |
10245433 | Alataris et al. | Apr 2019 | B2 |
10252048 | Loudin et al. | Apr 2019 | B2 |
10369369 | Perryman et al. | Aug 2019 | B2 |
10485980 | Yeh et al. | Nov 2019 | B2 |
11065461 | McBride et al. | Jul 2021 | B2 |
20010051807 | Grafton | Dec 2001 | A1 |
20020007204 | Goode | Jan 2002 | A1 |
20030050672 | Dahlberg | Mar 2003 | A1 |
20030078618 | Fey et al. | Apr 2003 | A1 |
20030139794 | Jenney et al. | Jul 2003 | A1 |
20030149468 | Wallsten | Aug 2003 | A1 |
20040143240 | Armstrong et al. | Jul 2004 | A1 |
20040164783 | Baru | Aug 2004 | A1 |
20040220665 | Hossainy et al. | Nov 2004 | A1 |
20050015048 | Chiu et al. | Jan 2005 | A1 |
20050112759 | Radisic et al. | May 2005 | A1 |
20050165465 | Pianca et al. | Jul 2005 | A1 |
20050182449 | Auge, II et al. | Aug 2005 | A1 |
20050267555 | Marnfeldt et al. | Dec 2005 | A1 |
20050267557 | Flynn et al. | Dec 2005 | A1 |
20050283202 | Gellman | Dec 2005 | A1 |
20060058598 | Esposito | Mar 2006 | A1 |
20060095078 | Tronnes | May 2006 | A1 |
20060121180 | Gertner et al. | Jun 2006 | A1 |
20060129216 | Hastings et al. | Jun 2006 | A1 |
20060282123 | Hunter et al. | Dec 2006 | A1 |
20070043410 | Boling | Feb 2007 | A1 |
20070100411 | Bonde | May 2007 | A1 |
20070142890 | Zarembo et al. | Jun 2007 | A1 |
20070261115 | Gerber et al. | Nov 2007 | A1 |
20070299491 | Borgaonkar et al. | Dec 2007 | A1 |
20080071340 | Atanasoska et al. | Mar 2008 | A1 |
20090043367 | Zilberman et al. | Feb 2009 | A1 |
20090099612 | Armstrong | Apr 2009 | A1 |
20090210040 | Ochoa | Aug 2009 | A1 |
20090259280 | Wilkin et al. | Oct 2009 | A1 |
20090281409 | Walter | Nov 2009 | A1 |
20090326611 | Gillbe | Dec 2009 | A1 |
20100198298 | Glukhovsky et al. | Aug 2010 | A1 |
20110282414 | Kothandaraman et al. | Nov 2011 | A1 |
20120232615 | Barolat et al. | Sep 2012 | A1 |
20130188397 | Wu et al. | Jul 2013 | A1 |
20130274829 | Gupta et al. | Oct 2013 | A1 |
20130282070 | Cowan et al. | Oct 2013 | A1 |
20140074186 | Faltys et al. | Mar 2014 | A1 |
20150148878 | Yoo et al. | May 2015 | A1 |
20150165186 | Dar et al. | Jun 2015 | A1 |
20150174418 | Tyler et al. | Jun 2015 | A1 |
20150328462 | Griffith | Nov 2015 | A1 |
20150335888 | Demers et al. | Nov 2015 | A1 |
20160121115 | Guillory et al. | May 2016 | A1 |
20160175585 | Gregory et al. | Jun 2016 | A1 |
20160346530 | Jeffery et al. | Dec 2016 | A1 |
20160346545 | Pal et al. | Dec 2016 | A1 |
20160361535 | Perryman et al. | Dec 2016 | A1 |
20170076414 | Egnal et al. | Mar 2017 | A1 |
20170182285 | Tyler et al. | Jun 2017 | A1 |
20170224990 | Goldwasser et al. | Aug 2017 | A1 |
20170368297 | Tyler et al. | Dec 2017 | A1 |
20180028824 | Pivonka et al. | Feb 2018 | A1 |
20180085593 | Fayram et al. | Mar 2018 | A1 |
20180256906 | Pivonka et al. | Sep 2018 | A1 |
20180272118 | Goldwasser et al. | Sep 2018 | A1 |
20180280708 | Escalona et al. | Oct 2018 | A1 |
20190051988 | Bern | Feb 2019 | A1 |
20190151659 | Mishra et al. | May 2019 | A1 |
20190374776 | Mishra et al. | Dec 2019 | A1 |
20200139138 | Sit et al. | May 2020 | A1 |
20200197710 | Harding et al. | Jun 2020 | A1 |
20200306528 | Linden et al. | Oct 2020 | A1 |
20210008376 | McBride et al. | Jan 2021 | A1 |
Number | Date | Country |
---|---|---|
204684455 | Oct 2015 | CN |
109603007 | Apr 2019 | CN |
111420281 | Jul 2020 | CN |
0862925 | Sep 1998 | EP |
1981589 | Apr 2016 | EP |
3449814 | Mar 2019 | EP |
2397233 | Jul 2004 | GB |
101653889 | Sep 2016 | KR |
WO-9848887 | Nov 1998 | WO |
WO-2005070494 | Aug 2005 | WO |
WO-2014093288 | Jun 2014 | WO |
WO-2015079319 | Jun 2015 | WO |
WO-2015183620 | Dec 2015 | WO |
WO-2016111974 | Jul 2016 | WO |
WO-2017041138 | Mar 2017 | WO |
WO-2021007340 | Jan 2021 | WO |
Entry |
---|
Becerra-Fajardo et al., “In Vivo Demonstration of Addressable Microstimulators Powered by Rectification of Epidermically Applied Currents for Miniaturized Neuroprostheses,” PLoS One (2015) 10(7): e0131666, 19 pages. |
“BioGlue Surgical Adhesive,” [online] CryoLife, Inc., [Retrieved on Jul. 10, 2008] Retrieved from the Internet: URL: http://www.cryolife.com/products/bioglue-surgical-adhesive, 2 pages. |
Bocan et al., “Adaptive Transcutaneous Power Transfer to Implantable Devices: A State of the Art Review.” Sensors, vol. 16, 393 (2016), 23 pages. |
Bossetti Design and Evaluation of a Transcutaneous Energy Transfer System, Department of Biomedical Engineering, Duke University, 2009, 188 pages. |
Brazel et al. “Modeling of Drug Release from Swellable Polymers” European Journal of Pharmaceutics and Biopharmaceutics, vol. 49 (2000) pp. 47-58. |
Brem et al., “Biocompatibility of a Biodegradable, Controlled-Release Polymer in the Rabbit Brain” Selective Cancer Therapeutics vol. 5, No. 2 (1989), pp. 55-65. |
Brem et al., “Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas” J. Neurosurg. vol. 74, (Mar. 1991), pp. 441-446. |
Brown et al., “Controlled Release of Insulin From Polymer Matrices: Control of Diabetes in Rats” Diabetes, vol. 35, (Jun. 1986), pp. 692-697. |
Chamberlin et al., “Analysis of the Charge Exchange Between the Human Body and Ground: Evaluation of ‘Earthing’ From an Electrical Perspective,” Journal of Chiropractic Medicine, vol. 13 (2014), pp. 239-246. |
Chizmadzhev et al., “Electrical Properties of Skin at Medium Voltages: Contribution of Appendageal Macropores,” Biophysical Journal, vol. 74 (Feb. 1998), pp. 843-856. |
Cosendai et al., “Magnetic Resonance Safety and RF Bion® Microstimulators,” 8th Annual Conference of the International Functional Electrical Stimulation Society (IFESS), Jul. 1-5, 2003, 3 pages. |
Davis et al., “Surgical Technique to insert and retrieve BIONs® (microstimulators) safely near deep Nerves for Functional Electrical Stimulation,” 7th Annual Conference of the International Functional Electrical Stimulation Society (IFESS), May 24, 2002, 3 pages. |
Deer et al., “Spinal Cord Stimulation for Refractory Angina Pectoris and Peripheral Vascular Disease,” Pain Physician, (2006); 9(4): 347-352. |
Gabriel “Compilation of the Dielectric Properties of Body Tissues at RF and Microwave Frequencies,” Final Technical Report for the Period Sep. 15, 1993 to Dec. 14, 1995 for the AFOSR/NL Bolling AFB DC 20332-0001, Feb. 1996, 271 pages. |
Gabriel “Compilation of the Dielectric Properties of Body Tissues at RF and Microwave Frequencies,” Final Technical Report for the Period Dec. 15, 1994 to Dec. 14, 1995 for the Armstrong Laboratory (AFMC) Brooks AFB TX 78235, Jun. 1996, 273 pages. |
Gabriel “Compilation of the Dielectric Properties of Body Tissues at RF and Microwave Frequencies,” Final Technical Report for the Period Sep. 15, 1993 to Dec. 14, 1994, for the Armstrong Laboratory (AFMC) Brooks AFB TX 78235, Jan. 1996, 21 pages. |
Gan et al., “The Stimulus Router: A Novel Means of Directing Current From Surface Electrodes to Nerves.” 10th Annual Conference of the International FES Society, Jul. 2005, pp. 21-23. |
Goodson, “Dental Applications,” Medical Applications of Controlled Release, vol. 2, Chapter 6, 1984, pp. 115-138. |
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2020/041234 dated Oct. 1, 2020, 13 pages. |
Ivorra et al., “Flexible Thread-like Electrical Stimulation Implants Based on Rectification of Epidermically Applied Currents Which Perform Charge Balance.” Replace, Repair, Restore, Relieve—Bridging Clinical and Engineering Solutions in Neurorehabilitation SE-67 (2014), pp. 447-455. |
Karpul et al., “Low-power Transcutaneous Current Stimulator for Wearable Applications.” BioMedical Engineering OnLine (2017) 16: pp. 1-13. |
Kwon et al., “Electrically Erodible Polymer Gel for Controlled Release of Drugs,” Nature, vol. 354, Nov. 28, 1991, pp. 291-293. |
Langer et al., “Polymers for the Sustained Release of Proteins and other Macromolecules” Nature. Oct. 28, 1976; 263(5580): 797-800. |
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate”. Science. Apr. 12, 1985; 228(4696): 190-2. |
Liu et al., “Five Valuable Functions of Blocking Capacitors in Stimulators.” 13th Annual International Conference of the FES Society (IFESS 2008), pp. 322-324. |
Masters et al., “Prolonged Regional Nerve Blockade by Controlled Release of Local Anesthetic from a Biodegradable Polymer Matrix” Anesthesiology. Aug. 1, 1993; 79(2): 340-6. |
Masters et al., “Sustained Local Anesthetic Release from Bioerodible Polymer Matrices: A Potential Method for Prolonged Regional Anesthesia” Pharmaceutical research. Oct. 1993; 10: 1527-32. |
Narasimhan et al., “Release Kinetics, Data Interpretation,” Encyclopedia of Controlled Drug Delivery, vol. 2, New York (1999), 17 pages. |
Nash “Controlled Release Systems for Contraception.” In R. Langer and D. Wise (eds.) Medical Applications of Controlled Release, vol. II Applications and Evaluation, CRC Press, Boca Rotan, FL (1984), pp. 35-64. |
Palti “Stimulation of muscles and nerves by means of externally applied electrodes,” Bulletin of the Research Council of Israel, Section E: Experimental Medicine, Jun. 1962, 10E(1): 54-56. |
Park et al., “Design and Implementation of Wireless Transcutaneous Electrical Nerve Stimulator (TENS) for Smart Phone.” IEICE Electronics Express, vol. 6, No. 22 (2009), pp. 1587-1594. |
Pless et al., “Tumor treating fields: concept, evidence and future,” Expert Opinion on Investigational Drugs, (2011) 20:8, 1099-1106. |
Prochazka “Functional Microstimulation of the Lumbosacral Spinal Cord” Neural Prosthesis Program Meeting, NIH Meeting, Nov. 2004, 5 pages. |
Shaikhutdinov et al., “Surface Properties of Polyacid-Poly (N-Vinyl Pyrrolidone) Complexes,” Colloid Journal. Nov. 2001; 63: 779-83. |
Sharon et al., “Development of Drug Delivery Systems for Use in Treatment of Narcotic Addiction” In R. E. Willette and G. Barnett (eds.), Naltrexone: Research Monograph 28, National Institute on Drug Abuse (1980) pp. 194-213. |
Taalla et al., “A Review on Miniaturized Ultrasonic Wireless Power Transfer to Implantable Medical Devices,” IEEE Access, Jan. 7, 2019, vol. 7, pp. 2092-2106. |
Trafton “Researchers Develop a Wireless Way to Power Human Implants,” SciTechDaily, Jun. 4, 2018, 4 pages, retrieved from https://scitechdaily.com/researchers-develop-wireless-way-to-power-human-implants/. |
Vargas Luna et al., “Dynamic Impedance Model of the Skin-Electrode Interface for Transcutaneous Electrical Stimulation.” PLoS One 10(5): e0125609 (May 2015), 15 pages. |
Voigt et al., “Cathodic-leading Pulses are More Effective Than Anodic-leading Pulses in Intracortical Microstimulation of the Auditory Cortex.” Journal of Neural Engineering. Mar. 19, 2019; 16(3), 15 pages. |
Yolles et al., “Sustained Delivery of Drugs From Polymer/Drug Mixtures” Polymer News. 1971; 1(4-5): 9-15. |
Supplementary European Search Report for European Patent Application 20837675.6, dated Nov. 9, 2023, 7 pages. |
Number | Date | Country | |
---|---|---|---|
20210346704 A1 | Nov 2021 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16504623 | Jul 2019 | US |
Child | 17379220 | US |